Security Snapshot

MEI Pharma, Inc. - Common Stock, $0.00000002 par value (MEIP) Institutional Ownership

CUSIP: 55279B202

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2023

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, $0.00000002 par value
Symbol
MEIP on Nasdaq
Shares outstanding
29,545,622
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • MEIP - MEI Pharma, Inc. - Common Stock, $0.00000002 par value is tracked under CUSIP 55279B202.
  • Latest finished 13F holder period is not available.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 1 to 0 between Q2 2023 and Q3 2023.
  • Reported value moved from $958,000 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC Evidence

Security key

55279B202

Latest holder period

n/a

13F holders

13D/G owners

1

CIK / CUSIP context first

MEIP full holder history Lite Strategy, Inc. SEC filings Lite Strategy, Inc. company facts Lite Strategy, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of MEI Pharma, Inc. - Common Stock, $0.00000002 par value (MEIP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Anson Funds Management LP 3.7% 1,093,188 Anson Funds Management LP 22 Jul 2025

Institutional Holders of MEI Pharma, Inc. - Common Stock, $0.00000002 par value (MEIP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2023 Q3 0 $0 -$958,000 0
2023 Q2 145,654 $958,000 -$28,712,302 $6.58 1
2023 Q1 48,845,759 $11,179,346 -$295,320 $0.23 45
2022 Q4 49,485,704 $12,052,989 -$1,007,880 $0.24 45
2022 Q3 47,607,776 $18,402,998 -$90,868 $0.39 55
2022 Q2 47,449,879 $28,704,093 -$5,095,402 $0.60 59
2022 Q1 56,055,550 $33,769,440 -$85,348,603 $0.60 85
2021 Q4 89,185,933 $238,011,275 +$60,987,652 $2.67 104
2021 Q3 65,176,813 $179,904,137 -$10,864,219 $2.76 100
2021 Q2 68,991,345 $196,726,475 -$5,446,204 $2.85 105
2021 Q1 70,784,540 $242,767,740 +$18,669,651 $3.43 105
2020 Q4 65,458,547 $172,902,331 -$2,754,748 $2.64 106
2020 Q3 66,088,757 $206,202,307 +$7,178,715 $3.12 100
2020 Q2 62,875,358 $259,680,491 +$1,477,050 $4.13 100
2020 Q1 64,570,596 $103,561,509 +$22,397,311 $1.61 77
2019 Q4 49,354,861 $122,400,810 +$24,179,217 $2.48 76
2019 Q3 36,909,319 $62,006,463 -$21,615,455 $1.68 69
2019 Q2 45,960,278 $114,897,440 +$11,724,666 $2.50 70
2019 Q1 41,010,769 $125,904,000 +$2,372,403 $3.07 62
2018 Q4 40,029,928 $105,434,000 +$7,721,183 $2.64 55
2018 Q3 36,164,953 $155,872,000 -$1,323,234 $4.31 59
2018 Q2 36,391,138 $143,378,000 +$111,542,358 $3.94 57
2018 Q1 8,504,579 $17,606,115 -$506,425 $2.07 42
2017 Q4 8,747,898 $18,344,388 -$186,571 $2.10 47
2017 Q3 8,638,250 $23,161,366 +$5,784,349 $2.68 53
2017 Q2 6,647,146 $15,883,000 +$1,199,231 $2.39 44
2017 Q1 6,302,427 $10,208,000 +$579,181 $1.62 42
2016 Q4 6,477,857 $9,326,000 +$440,611 $1.44 33
2016 Q3 5,522,709 $9,719,000 -$2,415,654 $1.76 36
2016 Q2 7,628,992 $10,371,000 -$3,091,435 $1.36 33
2016 Q1 9,938,127 $12,522,000 +$584,155 $1.26 36
2015 Q4 6,600,579 $10,561,000 +$592,477 $1.60 37
2015 Q3 6,217,539 $9,759,657 +$1,986,306 $1.57 33
2015 Q2 4,929,037 $8,428,000 -$5,402,971 $1.71 37
2015 Q1 7,979,253 $14,284,000 -$53,086,251 $1.79 41
2014 Q4 22,695,018 $96,926,463 +$35,679,904 $4.27 50
2014 Q3 12,032,981 $83,027,000 -$3,244,730 $6.90 33
2014 Q2 13,292,012 $84,269,801 -$19,517,998 $6.34 40
2014 Q1 13,970,941 $155,500,299 +$18,575,595 $11.13 48
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .